Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Nutrition and Metabolic Diseases Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Adv Nutr. 2022 Mar;13(2):455-473. doi: 10.1093/advances/nmab121. Epub 2023 Feb 10.
Previous studies have suggested that soy products may be beneficial for cardiometabolic health, but current evidence regarding their effects in type 2 diabetes (T2D) remains unclear. The aim of this systematic review and meta-analysis was to determine the impact of soy product consumption on cardiovascular risk factors in patients with T2D. PubMed, Scopus, Embase, and the Cochrane library were systematically searched from inception to March 2021 using relevant keywords. All randomized controlled trials (RCTs) investigating the effects of soy product consumption on cardiovascular risk factors in patients with T2D were included. Meta-analysis was performed using random-effects models and subgroup analysis was performed to explore variations by dose and baseline risk profile. A total of 22 trials with 867 participants were included in this meta-analysis. Soy product consumption led to a significant reduction in serum concentrations of triglycerides (TGs) [weighted mean difference (WMD): -24.73 mg/dL; 95% CI: -37.49, -11.97], total cholesterol (WMD: -9.84 mg/dL; 95% CI: -15.07, -4.61), LDL cholesterol (WMD: -6.94 mg/dL; 95% CI: -11.71, -2.17), and C-reactive protein (WMD: -1.27 mg/L; 95% CI: -2.39, -0.16). In contrast, soy products had no effect on HDL cholesterol, fasting blood sugar (FBS), fasting insulin, glycated hemoglobin, HOMA-IR, systolic blood pressure (SBP) and diastolic blood pressure, or BMI (all P ≥ 0.05). In subgroup analyses, there was a significant reduction in FBS after soy consumption in patients with elevated baseline FBS (>126 mg/dL) and in those who received higher doses of soy intake (>30 g/d). Moreover, soy products decreased SBP in patients with baseline hypertension (>135 mm Hg). Our meta-analysis suggests that soy product consumption may improve cardiovascular parameters in patients with T2D, particularly in individuals with poor baseline risk profiles. However, larger studies with longer durations and improved methodological quality are needed before firm conclusions can be reached.
先前的研究表明,大豆制品可能对心脏代谢健康有益,但目前关于其在 2 型糖尿病(T2D)中的作用的证据仍不清楚。本系统评价和荟萃分析的目的是确定大豆制品摄入对 T2D 患者心血管危险因素的影响。从创建到 2021 年 3 月,使用相关关键词系统地检索了 PubMed、Scopus、Embase 和 Cochrane 图书馆。纳入了所有研究大豆制品摄入对 T2D 患者心血管危险因素影响的随机对照试验(RCT)。使用随机效应模型进行荟萃分析,并进行亚组分析以探讨剂量和基线风险特征的变化。本荟萃分析共纳入 22 项试验,867 名参与者。大豆制品摄入可显著降低血清甘油三酯(TGs)浓度[加权均数差(WMD):-24.73 mg/dL;95%CI:-37.49,-11.97]、总胆固醇(WMD:-9.84 mg/dL;95%CI:-15.07,-4.61)、LDL 胆固醇(WMD:-6.94 mg/dL;95%CI:-11.71,-2.17)和 C 反应蛋白(WMD:-1.27 mg/L;95%CI:-2.39,-0.16)。相比之下,大豆制品对 HDL 胆固醇、空腹血糖(FBS)、空腹胰岛素、糖化血红蛋白、HOMA-IR、收缩压(SBP)、舒张压或 BMI 无影响(均 P ≥ 0.05)。亚组分析显示,在基线 FBS 升高(>126 mg/dL)和摄入较高剂量大豆(>30 g/d)的患者中,大豆摄入后 FBS 显著降低。此外,大豆制品可降低基线高血压(>135 mmHg)患者的 SBP。本荟萃分析表明,大豆制品摄入可能改善 T2D 患者的心血管参数,特别是在基线风险状况较差的患者中。然而,在得出明确结论之前,还需要进行更大规模、持续时间更长且方法学质量更高的研究。